|Bid||5,182.00 x 6100|
|Ask||5,186.00 x 13000|
|Day's Range||5,184.00 - 5,205.00|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||19.42|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||2.80 (4.23%)|
|1y Target Est||66.82|
AstraZeneca’s (AZN) business is separated into four segments: Respiratory, Cardiovascular and Metabolic Diseases (or CVMD), Oncology, and Other.
AstraZeneca (AZN) reported a fall of ~12% in its top line to $5.4 billion in 1Q17. This fall included an operational fall of ~10% and a 2% negative impact of foreign exchange.
In 1Q17, AstraZeneca surpassed Wall Street analysts’ estimates, reporting earnings per share (or EPS) of $0.42 on revenue of $5.40 billion.